^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Multiple Myeloma

    1d
    Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma (clinicaltrials.gov)
    P=N/A, N=144, Recruiting, University Health Network, Toronto | N=80 --> 144 | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date
    1d
    Real MM: STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA (clinicaltrials.gov)
    P4, N=450, Active, not recruiting, University of Turin, Italy | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    lenalidomide • bortezomib • prednisone • melphalan • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    1d
    Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant (clinicaltrials.gov)
    P2, N=120, Suspended, University of Utah | Recruiting --> Suspended | Trial primary completion date: Jan 2026 --> May 2026
    Trial suspension • Trial primary completion date
    |
    CD34 (CD34 molecule)
    1d
    A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (clinicaltrials.gov)
    P1, N=64, Recruiting, AstraZeneca | N=20 --> 64
    Enrollment change
    |
    AZD0120
    1d
    OPTIMUS-EL: Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy (clinicaltrials.gov)
    P2, N=40, Recruiting, Seoul National University Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Elrexfio (elranatamab-bcmm)
    1d
    AI-derived five-gene signature predicts risk in multiple myeloma under bortezomib-based therapy. (PubMed, Sci Rep)
    This model underscores the pivotal role of TME components in shaping therapeutic outcomes and offers a scalable, clinically translatable tool for personalized risk stratification. Our findings highlight the necessity of integrating microenvironmental insights into MM prognostication and pave the way for microenvironment-informed therapeutic decision-making.
    Journal • Gene Signature
    |
    RBM10 (RNA Binding Motif Protein 10) • SDC1 (Syndecan 1) • SOX11 (SRY-Box Transcription Factor 11)
    |
    bortezomib
    2d
    Trilogy-4: A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=400, Not yet recruiting, Janssen Research & Development, LLC
    New P3 trial
    |
    JNJ-5322 • Tecvayli (teclistamab-cqyv)
    2d
    A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma (clinicaltrials.gov)
    P2, N=21, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    lenalidomide • Onureg (azacitidine oral)
    2d
    Characterizing circulating rare cells in peripheral blood for detecting and monitoring multiple myeloma and precursor states. (PubMed, NPJ Precis Oncol)
    Shifts in BCMA and CD45 expression suggested immune cell profile alterations with progression and treatment. These findings underscore PB-based liquid biopsy as a promising tool for MM detection and monitoring, revealing circulating PC heterogeneity.
    Journal • IO biomarker
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • SDC1 (Syndecan 1)
    |
    PTPRC expression
    2d
    Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE) (clinicaltrials.gov)
    P=N/A, N=2555, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed
    2d
    Distinct immunophenotypic profiles of circulating tumor plasma cells in MGUS and smoldering multiple myeloma. (PubMed, Int J Hematol)
    Serum soluble B cell maturation antigen levels did not differ between patients with or without detectable CTPCs in MGUS or SMM. These findings highlight the distinct phenotypic and cytogenetic characteristics of CTPCs in MGUS and SMM, and provide insights regarding their biological features and pathogenesis.
    Journal • IO biomarker
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD38 (CD38 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1) • CD200 (CD200 Molecule) • CD81 (CD81 Molecule)
    |
    Chr t(11;14)
    3d
    Solitary Plasmacytoma of the Rib: A Report of a Rare Case. (PubMed, Am J Case Rep)
    Early intervention and regular monitoring optimize outcomes and reduce misdiagnosis risks. Regular follow-up is vital to detect disease changes early and adjust treatment plans promptly.
    Journal
    |
    SDC1 (Syndecan 1)